Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Rastelli

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Schizophrenia Bulletin|June 16, 2022
Tool-use Extends Peripersonal Space Boundaries in Schizophrenic PatientsFrancesca Ferroni, Martina Ardizzi, Francesca Magnani, et al.
Neuromuscular Disorders : NMD|July 21, 2020
A novel, pathogenic dinucleotide deletion in the mitochondrial MT-TY gene causing myasthenia-like featuresAlbert Z Lim, Grace McMacken, Francesca Rastelli, et al.
Lung Cancer (Amsterdam, Netherlands)|December 4, 2003
Phase II study of gemcitabine-cisplatin-paclitaxel triplet as induction chemotherapy in inoperable, locally-advanced non-small cell lung cancerFederico Cappuzzo, Filippo De Marinis, Fabrizio Nelli, et al.
Cancers|July 14, 2023
Impact of Signet-Ring Cell Histology in the Management of Patients with Non-Metastatic Gastric Cancer: Results from a Retrospective Multicenter Analysis Comparing FLOT Perioperative Chemotherapy vs. Surgery Followed by Adjuvant ChemotherapyRiccardo Giampieri, Maria Giuditta Baleani, Alessandro Bittoni, et al.
BJU International|June 30, 2018
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programmeUgo De Giorgi, Giacomo Cartenì, Diana Giannarelli, et al.
Journal for Immunotherapy of Cancer|April 5, 2019
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access programElena Verzoni, Giacomo Cartenì, Enrico Cortesi, et al.
Journal of Translational Medicine|November 16, 2019
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practiceAlessio Cortellini, Maria G Vitale, Federica De Galitiis, et al.
HGG Advances|March 24, 2022
Biallelic variants in <i>TAMM41</i> are associated with low muscle cardiolipin levels, leading to neonatal mitochondrial diseaseKyle Thompson, Lucas Bianchi, Francesca Rastelli, et al.
Thoracic Cancer|December 23, 2021
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapyGiuseppe L Banna, Marcello Tiseo, Diego L Cortinovis, et al.
European Journal of Cancer (Oxford, England : 1990)|February 29, 2020
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse eventsAlessio Cortellini, Melissa Bersanelli, Daniele Santini, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Schizophrenia Bulletin|June 16, 2022
Tool-use Extends Peripersonal Space Boundaries in Schizophrenic PatientsFrancesca Ferroni, Martina Ardizzi, Francesca Magnani, et al.
Neuromuscular Disorders : NMD|July 21, 2020
A novel, pathogenic dinucleotide deletion in the mitochondrial MT-TY gene causing myasthenia-like featuresAlbert Z Lim, Grace McMacken, Francesca Rastelli, et al.
Lung Cancer (Amsterdam, Netherlands)|December 4, 2003
Phase II study of gemcitabine-cisplatin-paclitaxel triplet as induction chemotherapy in inoperable, locally-advanced non-small cell lung cancerFederico Cappuzzo, Filippo De Marinis, Fabrizio Nelli, et al.
Cancers|July 14, 2023
Impact of Signet-Ring Cell Histology in the Management of Patients with Non-Metastatic Gastric Cancer: Results from a Retrospective Multicenter Analysis Comparing FLOT Perioperative Chemotherapy vs. Surgery Followed by Adjuvant ChemotherapyRiccardo Giampieri, Maria Giuditta Baleani, Alessandro Bittoni, et al.
BJU International|June 30, 2018
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programmeUgo De Giorgi, Giacomo Cartenì, Diana Giannarelli, et al.
Journal for Immunotherapy of Cancer|April 5, 2019
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access programElena Verzoni, Giacomo Cartenì, Enrico Cortesi, et al.
Journal of Translational Medicine|November 16, 2019
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practiceAlessio Cortellini, Maria G Vitale, Federica De Galitiis, et al.
HGG Advances|March 24, 2022
Biallelic variants in <i>TAMM41</i> are associated with low muscle cardiolipin levels, leading to neonatal mitochondrial diseaseKyle Thompson, Lucas Bianchi, Francesca Rastelli, et al.
Thoracic Cancer|December 23, 2021
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapyGiuseppe L Banna, Marcello Tiseo, Diego L Cortinovis, et al.
European Journal of Cancer (Oxford, England : 1990)|February 29, 2020
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse eventsAlessio Cortellini, Melissa Bersanelli, Daniele Santini, et al.
Pageof 4